Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

BACKGROUND: Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitinib activity and clinical benefit in patients with pNET and carcinoid tumours in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385961/
https://www.ncbi.nlm.nih.gov/pubmed/25756398
http://dx.doi.org/10.1038/bjc.2015.73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385961/
https://www.ncbi.nlm.nih.gov/pubmed/25756398
http://dx.doi.org/10.1038/bjc.2015.73

Ejemplares similares